medigraphic.com

2022, Number 3

<< Back Next >>

Enf Infec Microbiol 2022; 42 (3)

SARS-COV-2associated with pediatric multisystem inflammatory syndrome: on purpose of two cases

Sánchez GJM, Castellanos MJM, Portillo GJH, Castellanos-Gutiérrez A, Lazcano BS

Language: Spanish
References: 35
Page: 106-114
PDF size: 258.71 Kb.


ABSTRACT

Since the start of the COVID-19 pandemic, most publications have documented that approximately 97-98% of registered cases occurred in adults, with greater severity and complications in those with comorbidities. Of the remaining percentage (2 to 3%) that occurred in children, the majority had mild or asymptomatic infection or mild respiratory symptoms. However, cases have been documented in children who developed severe manifestations, characterized by a multisystemic inflammatory process, even in sometimes defined as atypical or incomplete Kawasaki disease type. Over time, new findings have been incorporated whose clinical characteristics include persistent fever, multiorgan involvement, with elevated inflammatory biomarkers, which has been described as a pediatric multisystemic inflammatory syndrome (PMIS). In recent times, with the presence of the omicron variant, infections and incidence in children in our country have increased, also presenting with a greater number of warning signs and symptoms, as well as their severity. We review the literature of similar cases, highlighting the importance of timely diagnosis, more useful biomarkers, and follow-up. We describe the clinical picture, treatment and evolution of two cases infected by SARS-COV-2 with a compatible process due to its clinical characteristics associated with moderate PMIS. With the aim of alerting about the greater occurrence in children of the pmis and promoting the best timely treatment and inquiring about the reduction of sequelae in the medium and long term, as well as the probability of organic damage and therefore years of life with disability.


REFERENCES

  1. Organización Mundial de la Salud (oms), “Tablero deemergencias sanitarias. oms (covid-19)”. Disponible en:https://covid19.who.int/region/amro/country/mx.

  2. Organización Mundial de la Salud (oms), “Alocución delDirector General de la oms en la rueda de prensa sobrela covid-19, celebrada el 8 de mayo de 2020”. Disponibleen: https://www.who.int/es/director-general/speeches/detail/who-director-general-s-opening-remarks-at-themedia-briefing-on-covid-19---8-may-2020.

  3. Riphagen, S., Gómez, X,. González-Martínez, C., Wilkinson,N. y Theocharis, P., “Hyperinflammatory shock inchildren during the covid-19 pandemic”, Lancet, 2020,395: 1607-1608. doi: 10.1016/S01406736(20)31094-1Epub 2020 7 de mayo.

  4. Verdoni, L., Mazza, A., Gervasoni, A., Martelli, L., Ruggeri,M., Ciuffreda, M. et al., “An outbreak of severeKawasaki-like illness in the Italian epicenter of the sarscov-2 epidemic: an observational cohort study”, Lancet,2020, 13 de mayo. doi: 10.1016/S01406736(20)31103-X.

  5. Soma, V.L., Shust, G.F. y Ratner, A.J., “Multisystem inflammatorysyndrome in children”, Curr Opin Pediatr, 2021,33 (1): 152-158. doi: 10.1097/MOP.0000000000000974.

  6. Jones, V.G., Mills, M., Suárez, D. et al., “covid-19 andKawasaki disease: novel virus and novel case”, HospPediatr, 2020, 123.

  7. Verdoni, L., Mazza, A., Gervasoni, A., Martelli, L., Ruggeri,M., Ciuffreda, M., Bonanomi, E. y D’Antiga, L., “Anoutbreak of severe Kawasaki-like disease at the Italianepicentre of the sars-cov-2 epidemic: an observationalcohort study”, Lancet, 2020, 395: 1771.

  8. DeBiasi, R.L., Song, X., Delaney, M., Bell, M., Smith, K.,Pershad, J. et al., “Severe covid-19 in children and youngadults in the Washington, DC Metropolitan Region”, JPediatr, 2020, (20): 30581-30583.

  9. Mahase, E., “covid-19: sases of inflammatory syndromein children surge after urgent alert”, bmj, 2020, 369:1990.

  10. Belhadjer, Z., Méot, M., Bajolle, F., Khraiche, D., Legendre,A., Abakka, S. et al., “Acute heart failure in multisysteminflammatory syndrome in children (mis-c) in thecontext of the global sars-cov-2 pandemic”, 17 de mayode 2020; doi: 10.1161/circulación aha.120.048360.

  11. DeBiasi, R.L., Song, X., Delaney, M., Bell, M., Smith,K., Pershad, J. et al., “covid-19 severe in children andyoung adults in the Washington, DC MetropolitanRegion”, J Pediatr, 2020, 13 de mayo. doi: 10.1016/j.peds.2020.05.007. En línea antes de la impresión.

  12. Toubiana, J., Poirault, C., Corsia, A., Bajolle, F., Fourgeaud,J., Angoulvant, F. et al., “Kawasaki diseaseoutbreak in children during the covid-19 pandemic: aprospective observational study in Paris, France”, 14 demayo de 2020. doi: https://doi.org/10.1101/2020.05.10.20097394.

  13. Deza León, M.P., Redzepi, A., McGrath, E., Abdel-Haq,N., Shawaqfeh, A., Sethuraman, U. et al., “Pediatricmultisystem inflammatory syndrome associated withcovid-19”, J Pediatric Infections Dis, 2020, 22 de mayo.doi: 10.1093/jpids/piaa061.

  14. Soma, V.L., Shust, G.F., Ratner, A.J., “Multisystem inflammatorysyndrome in children”, Curr Opin Pediatr, 2021,33 (1): 152-158. doi: 10.1097/MOP.0000000000000974.

  15. Montaño-Luna, V.E. y Miranda-Novales, M.G., “Updateon clinical management of covid-19 in pediatric patients:after a year of pandemic”, Rev Mex Pediatr, 2021, 88 (1):31-45. doi.org/10.35366/99417.

  16. Sánchez-González, J.M., Portillo-Gallo, J.H., Ishida-Gutiérrez,C., Rivera-Cisneros, A.E. y Franco Santillán, R.,“igg anti- sars-cov-2 antibodies and their correlation withclinical signs and symptoms in Northern Mexico”, RevMex Infectología y Microbiología, 2022, 42. Aceptadopara publicación.

  17. Gallo Marín, B., Aghagoli, G., Lavine, K., Yang, L., Siff,E.J., Chiang, S.S., Salazar-Mather, T.P., Dumenco, L.,Savaria, M.C., Aung, S.N., Flanigan, T. y Michelow, I.C.,“Predictors of the severity of covid-19: a review of theliterature”, Medical Virology, 2021, 31 (1): 1-10. Disponibleen: htps://doi.org/10.1002/rmv.2146.

  18. De Souza, T.H., Nadal, J.A., Nogueira, R.J.N., Pereira,R.M. y Brandão, M.B., “Clinical manifestations of childrenwith covid-19: a systematic review”, Pediatr Pulmonol,2020, 55 (8): 1892-1899. Disponible en: https://doi.org/10.1002/ppul.24885.

  19. covid-19 Treatment Guidelines Panel, “Coronavirus disease

  20. 2019 (covid-19) treatment guidelines”, NationalInstitutes of Health. Disponible en: https://files.covid-19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf.20. Whittaker, E., Bamford, A., Kenny, J., Kaforou, M., Jones,C.E., Shah, P. et al., “Clinical characteristics of 58children with a pediatric inflammatory multisystem syndrometemporally associated with sars-cov-2”, jama,2020, 324 (3): 259-269. doi: 10.1001/jama.2020.10369.

  21. World Health Organization (who), “Multisystem inflammatorysyndrome in children and adolescents temporallyrelated to covid-19”, 2020. Disponible en: https://www.who.int/news-room/commentaries/detail/multisysteminflammatory-syndrome-in-children and-adolescents-withcovid-19.

  22. Kaushik, S., Aydin, S.I., Derespina, K.R., Bansal, P.B.,Kowalsky, S., Trachtman, R. et al., “Multisystem inflammatorysyndrome in children associated withsevere acute respiratory syndrome coronavirus 2 infection(mis-c): a multi-institutional study from NewYork City”, J Pediatr, 2020, 224: 24-29. doi: 10.1016/j.jpeds.2020.06.045.

  23. Agarwal, A., Chen, A. y Ravindran, N., “Gastrointestinaland liver manifestations of covid-19”, Journal Of ClinicalAnd Experimental Hepatology. Disponible en: https://doi.org/10.1016/j.jceh.2020.03.001.

  24. Xu, L., Liu, J., Lu, M., Yang, D. y Zheng, X., “Liver injuryduring highly pathogenic human coronavirus infections”,Liver Int, 2020, 40 (5): 998-1004.

  25. Jin, X., Lian, J.S., Hu, J.H. et al., “Epidemiological, clinicaland virological characteristics of 74 cases ofcoronavirus- infected disease 2019 (covid-19) with gastrointestinalsymptoms”, Gut, 2020. doi: 10.1136/gutjnl-2020-320926.

  26. Chai, X., Hu, L., Zhang, Y. et al., “Specific ace2 expressionin cholangiocytes may cause liver damage after2019-ncov infection. Disponible en: https://doi.org/10.1101/2020.02.03.931766.

  27. Castagnoli, R., Votto, M., Licari, A. et al., “Severe acuterespiratory syndrome coronavirus 2 (sars-cov-2) infectionin children and adolescents: a systematic review”,jama Pediatr, 2020, 1467.

  28. Dong, Y., Mo, X., Hu, Y., Qi, X., Jian, F., Jian, K. et al.,“Epidemiology of covid-19 among children in China”,Pediatrics, 2020, 145 (6): e20200702. Disponible en:https://pediatrics.aappubiications.org/content/145/6/e20200702.

  29. Matthai, J., Shanmugam, N. y Sobhan, P., Indian Societyof Pediatric Gastroenterology hpan, Pediatrics pgcoiao,Coronavirus disease (covid-19) and the gastrointestinalsystem in children”, Indian Pediatr, 2020.

  30. Zhao, Y., Patel, J., Huang, Y., Yin, L. y Tang, L., “Cardiacmarkers of multisystem inflammatory syndromein children (mis-c) in covid-19 patients: a meta-analysis”,Am J Emerg Med, 2021, 49: 62-70. doi:10.1016/j.ajem.2021.05.044.

  31. Güllü, U.U., Güngör, Ş., İpek, S., Yurttutan, S. y Dilber, C.,“Predictive value of cardiac markers in the prognosis ofcovid-19 in children”, Am J Emerg Med, 2021, 48: 307-311. doi:10.1016/j.ajem.2021.06.075.

  32. Pouletty, M., Borocco, C., Ouldali, N. et al., “Paediatricmultisystem inflammatory syndrome temporally associatedwith sars-cov-2 mimicking Kawasaki disease(Kawa-covid-19): a multicentre cohort”, Annals of theRheumatic Diseases, 2020, 79: 999-1006.

  33. Xie, Y., Xu, E., Bowe, B. et al., “Long-term cardiovascularoutcomes of covid-19”, Nat Med, 2022. Disponible en:https://doi.org/10.1038/s41591-022-01689-3.

  34. Ieva, R. Smane, L., Anda, K.U., Zanda, P., Iveta, R., Lizete,K. y Pavare, J., “Comparison of persistent symptomsafter covid-19 and other non-sars-cov-2 infectionschildren”, Frontiers in Pediatrics, 2021, 9 (1):13. doi:10.3389/fped.2021.752385. Disponible en: https://www.frontiersin.org/article/10.3389/fped.2021.752385.

  35. Daugherty, S.E,, Guo, Y., Heath, K., Dasmariã, M.C.,Jubilo, K.G., Samranvedhya, J. et al., “Risk of clinicalsequelae after the acute phase of sars-cov-2 infection:retrospective cohort study”, bmj, 2021, 373: 1098.doi:10.1136/bmj.n1098.




2020     |     www.medigraphic.com